SunTrust Banks, Inc. Increases Nabriva Therapeutics AG (NBRV) Price Target to $24.00
Nabriva Therapeutics AG (NASDAQ:NBRV) had its price target raised by SunTrust Banks, Inc. from $20.00 to $24.00 in a report released on Monday. SunTrust Banks, Inc. currently has a buy rating on the biotechnology company’s stock.
Several other research firms have also commented on NBRV. Cantor Fitzgerald reissued an overweight rating on shares of Nabriva Therapeutics AG in a research report on Friday, June 23rd. HC Wainwright reissued a buy rating and issued a $16.00 price objective on shares of Nabriva Therapeutics AG in a research report on Friday, June 30th. Zacks Investment Research downgraded Nabriva Therapeutics AG from a hold rating to a sell rating in a research note on Wednesday, July 12th. Finally, ValuEngine upgraded Nabriva Therapeutics AG from a sell rating to a hold rating in a research note on Saturday, June 24th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus price target of $19.13.
Shares of Nabriva Therapeutics AG (NBRV) opened at 8.35 on Monday. The firm’s market capitalization is $224.10 million. The stock has a 50 day moving average price of $9.01 and a 200-day moving average price of $10.19. Nabriva Therapeutics AG has a 52 week low of $3.52 and a 52 week high of $14.10.
Nabriva Therapeutics AG (NASDAQ:NBRV) last released its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($5.83) by $5.29. The company had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $1.34 million. On average, analysts anticipate that Nabriva Therapeutics AG will post ($2.29) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “SunTrust Banks, Inc. Increases Nabriva Therapeutics AG (NBRV) Price Target to $24.00” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/suntrust-banks-inc-increases-nabriva-therapeutics-ag-nbrv-price-target-to-24-00/1579770.html.
In other news, major shareholder Vivo Capital Viii, Llc purchased 52,631 shares of the firm’s stock in a transaction that occurred on Monday, September 18th. The stock was acquired at an average cost of $9.46 per share, for a total transaction of $497,889.26. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Hbm Healthcare Investments (Ca sold 8,558 shares of Nabriva Therapeutics AG stock in a transaction dated Thursday, June 29th. The stock was sold at an average price of $10.96, for a total value of $93,795.68. Following the completion of the transaction, the insider now owns 2,591,396 shares of the company’s stock, valued at $28,401,700.16. The disclosure for this sale can be found here. Insiders sold 279,000 shares of company stock valued at $2,870,869 over the last quarter. Insiders own 2.75% of the company’s stock.
A number of large investors have recently bought and sold shares of NBRV. Royal Bank of Canada grew its stake in Nabriva Therapeutics AG by 19.6% in the second quarter. Royal Bank of Canada now owns 52,807 shares of the biotechnology company’s stock worth $553,000 after purchasing an additional 8,650 shares in the last quarter. Almanack Investment Partners LLC. grew its stake in Nabriva Therapeutics AG by 482.2% in the second quarter. Almanack Investment Partners LLC. now owns 907,183 shares of the biotechnology company’s stock worth $1,633,000 after purchasing an additional 751,366 shares in the last quarter. Nationwide Fund Advisors grew its stake in Nabriva Therapeutics AG by 4.6% in the second quarter. Nationwide Fund Advisors now owns 180,924 shares of the biotechnology company’s stock worth $2,032,000 after purchasing an additional 7,924 shares in the last quarter. Finally, Wellington Management Group LLP grew its stake in Nabriva Therapeutics AG by 9.9% in the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock worth $25,830,000 after purchasing an additional 193,951 shares in the last quarter. Institutional investors and hedge funds own 68.56% of the company’s stock.
About Nabriva Therapeutics AG
Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.
Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with Analyst Ratings Network's FREE daily email newsletter.